Market Cap : 8.39 B | Enterprise Value : 7.55 B | PE Ratio : At Loss | PB Ratio : 18.35 |
---|
NAS:NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. NovoCure's total current liabilities for the quarter that ended in Mar. 2022 was $127.8
The historical data trend for NovoCure's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
NovoCure's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 124.84 | + | 0 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 0 | + | 17.762 | |
= | 142.6 |
NovoCure's Total Current Liabilities for the quarter that ended in Mar. 2022 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 127.799 | + | 0 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 0 | + | 0 | |
= | 127.8 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of NovoCure's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Weinberg Uri | officer: Chief Science Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Groenhuysen Wilhelmus Cm | officer: Chief Operating Officer | C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654 |
Danziger Asaf | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302 |
Leung Gabriel | director | C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960 |
Shah Pritesh | officer: Chief Commercial Officer | C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Leonard Frank X | officer: Chief Development Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Cordova Ashley | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Madden Martin J. | director | C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043 |
Benaim Ely | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 |
Doyle William F | director, officer: Executive Chairman | PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Ambrogi Michael J. | officer: Chief Operating Officer | 195 COMMERCE WAY PORTSMOUTH NH 03801 |
Longsworth Todd Christopher | officer: General Counsel | NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Hilleman Jeryl L | director | C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025 |
Mccoy Sherilyn S | director | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Hung David | director | C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
From GuruFocus
Other Sources
By Fool 2021-07-29
By Zacks 2022-02-24
By Fool 2022-01-29
By Seekingalpha 2022-01-01
By Zacks 2022-02-03
By Zacks 2021-10-28
By Fool 2021-10-14
By tipranks.com 2022-03-05
By Fool 2021-07-30
By Seekingalpha 2021-11-30
By Zacks 2022-02-16